Pure Bioscience Capital Expenditures (CapEx) Growth & History (PURE)
Pure Bioscience's capital expenditures (capex) was $33,000 for fiscal 2023.
View full Pure Bioscience company overviewPure Bioscience annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-07-31 | $33,000 | −$48,000 | −59.26% |
| 2022 | 2022-07-31 | $81,000 | −$440,000 | −84.45% |
| 2021 | 2021-07-31 | $521,000 | $463,000 | +798.28% |
| 2020 | 2020-07-31 | $58,000 | $51,000 | +728.57% |
| 2019 | 2019-07-31 | $7,000 | −$12,000 | −63.16% |
| 2018 | 2018-07-31 | $19,000 | −$187,000 | −90.78% |
| 2017 | 2017-07-31 | $206,000 | −$184,000 | −47.18% |
| 2016 | 2016-07-31 | $390,000 | $309,000 | +381.48% |
| 2015 | 2015-07-31 | $81,000 | $60,000 | +285.71% |
| 2014 | 2014-07-31 | $21,000 | $9,000 | +75.00% |
| 2013 | 2013-07-31 | $12,000 | $2,000 | +20.00% |
| 2012 | 2012-08-14 | $10,000 | −$4,000 | −28.57% |
| 2011 | 2011-07-31 | $14,000 | — | — |
Pure Bioscience quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q4 2023 | 2023-07-31 | $43,000 | $26,000 | +152.94% |
| Q3 2023 | 2023-04-30 | $39,000 | $28,000 | +254.55% |
| Q2 2023 | 2023-01-31 | $0 | −$1,000 | — |
| Q1 2023 | 2022-10-31 | $37,000 | −$17,000 | −31.48% |
| Q4 2022 | 2022-07-31 | $17,000 | $0 | 0.00% |
| Q3 2022 | 2022-04-30 | $11,000 | $11,000 | — |
| Q2 2022 | 2022-01-31 | $1,000 | −$329,000 | −99.70% |
| Q1 2022 | 2021-10-31 | $54,000 | −$120,000 | −68.97% |
| Q4 2021 | 2021-07-31 | $17,000 | — | — |
| Q3 2021 | 2021-04-30 | $0 | $0 | — |
| Q2 2021 | 2021-01-31 | $330,000 | — | — |
| Q1 2021 | 2020-10-31 | $174,000 | — | — |
| Q3 2020 | 2020-04-30 | $0 | −$2,000 | — |
| Q4 2019 | 2019-07-31 | $1,000 | $1,000 | — |
| Q3 2019 | 2019-04-30 | $2,000 | $1,000 | +100.00% |
| Q2 2019 | 2019-01-31 | $0 | −$11,000 | — |
| Q1 2019 | 2018-10-31 | $8,000 | −$1,000 | −11.11% |
| Q4 2018 | 2018-07-31 | $0 | −$1,000 | — |
| Q3 2018 | 2018-04-30 | $1,000 | −$31,000 | −96.88% |
| Q2 2018 | 2018-01-31 | $11,000 | −$86,000 | −88.66% |
| Q1 2018 | 2017-10-31 | $9,000 | −$67,000 | −88.16% |
| Q4 2017 | 2017-07-31 | $1,000 | −$198,000 | −99.50% |
| Q3 2017 | 2017-04-30 | $32,000 | −$151,000 | −82.51% |
| Q2 2017 | 2017-01-31 | $97,000 | $93,000 | +2325.00% |
| Q1 2017 | 2016-10-31 | $76,000 | $72,000 | +1800.00% |
| Q4 2016 | 2016-07-31 | $199,000 | $137,000 | +220.97% |
| Q3 2016 | 2016-04-30 | $183,000 | $170,000 | +1307.69% |
| Q2 2016 | 2016-01-31 | $4,000 | $2,000 | +100.00% |
| Q1 2016 | 2015-10-31 | $4,000 | $0 | 0.00% |
| Q4 2015 | 2015-07-31 | $62,000 | $62,000 | — |
| Q3 2015 | 2015-04-30 | $13,000 | $13,000 | — |
| Q2 2015 | 2015-01-31 | $2,000 | −$8,000 | −80.00% |
| Q1 2015 | 2014-10-31 | $4,000 | −$7,000 | −63.64% |
| Q4 2014 | 2014-07-31 | $0 | $0 | — |
| Q3 2014 | 2014-04-30 | $0 | −$1,000 | — |
| Q2 2014 | 2014-01-31 | $10,000 | $2,000 | +25.00% |
| Q1 2014 | 2013-10-31 | $11,000 | $8,000 | +266.67% |
| Q4 2013 | 2013-07-31 | $0 | −$1,000 | — |
| Q3 2013 | 2013-04-30 | $1,000 | $1,000 | — |
| Q2 2013 | 2013-01-31 | $8,000 | −$1,000 | −11.11% |
| Q1 2013 | 2012-10-31 | $3,000 | $3,000 | — |
| Q4 2012 | 2012-08-14 | $1,000 | −$128,000 | −99.22% |
| Q3 2012 | 2012-04-30 | $0 | −$1,000 | — |
| Q2 2012 | 2012-01-31 | $9,000 | −$93,000 | −91.18% |
| Q1 2012 | 2011-10-31 | $0 | −$40,000 | — |
| Q4 2011 | 2011-07-31 | $129,000 | — | — |
| Q3 2011 | 2011-04-30 | $1,000 | — | — |
| Q2 2011 | 2011-01-31 | $102,000 | — | — |
| Q1 2011 | 2010-10-31 | $40,000 | — | — |
Pure Bioscience capital expenditures (capex) trends
Over the last five fiscal years, Pure Bioscience's capital expenditures (capex) increased from $19,000 to $33,000, a change of $14,000. The latest reported quarter, Q4 2023, shows $43,000.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pure Bioscience source filings ↗